Drug intelligence / Profile preview

SYHA1805

Development stage: Phase 1
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

SYHA1805 is a novel small-molecule agonist of the farnesoid X receptor (FXR), developed primarily for the treatment of nonalcoholic steatohepatitis (NASH). It is administered orally and is currently in early-phase clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Preclinical studies suggest that SYHA1805 has high selectivity for its target and can significantly ameliorate liver fibrosis, with promising efficacy and safety profiles. There are currently no other products of this specific type available globally[1][3][4][6].

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on SYHA1805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYHA1805.

Explore the full profile